PanoSpace
Develops extrusion-based and melt electrowriting bioprinting systems for tissue engineering and regenerative medicine.
- CEO / Founder
- Guo Min
- Team Size
- 11-50
- Stage
- Operational
- Total Funding
- $5M
- Latest Round
- Pre-Series A
- Key Investors
- CAS Star (Zhongke Chuangxing); ZGC Group (Zhongguancun Development Group)
Technology & Products
Key Products
BiOne; BioPro; BioLab; MEW
Technological Advantage
Offers a range of bioprinting systems from laboratory-scale (BioLab) to professional-grade (BioPro), integrating both standard extrusion and advanced MEW processes.
Differentiation
Value Proposition
Provides high-precision bioprinting platforms including Melt Electrowriting (MEW) for micro-scale tissue structures and regenerative medicine applications.
How They Differentiate
Focuses on the integration of Melt Electrowriting (MEW) alongside traditional extrusion bioprinting to enable micro-scale structural control in tissue engineering.
Market & Competition
Target Customers
Biomedical researchers, tissue engineers, and pharmaceutical R&D departments.
Industry Verticals
Medical; Biotechnology; Pharmaceuticals
Competitors
CELLINK; Organovo; Poietis; EnvisionTEC; Rokit
Growth & Milestones
Growth Metrics
Raised tens of millions of RMB in 2021; Systems deployed in 50+ research and medical institutions across China.
Major Milestones
2014: Company founded in Beijing; 2017: Secured Angel funding from ZGC Group; 2020: Released the BioPro and MEW series printers; 2021: Completed Pre-Series A funding round led by CAS Star
Notable Customers
Peking University Third Hospital; Tsinghua University; Beijing Institute of Technology; Chinese Academy of Sciences